Following People With Epstein-Barr Virus-Related T/NK-Cell Lymphoma and Related Diseases
Follows adults with Epstein-Barr virus-related T/NK-cell lymphomas, tracking treatment, outcomes and blood markers.
Key facts
- Who runs it
- Rong Tao
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- 11 Aug 2026
- Expected to end
- 31 Dec 2035
- Type of study
- Observational, 2 groups
- Record updated
- 13 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults newly diagnosed with an Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease. No treatment is assigned; the study follows patients and collects blood samples.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease. Past cohort: extranodal NK/T-cell lymphoma diagnosed between January 1, 2017 and December 31, 2025. New cohort: extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, or Epstein-Barr virus-positive nodal T/NK-cell lymphoma, diagnosed between June 1, 2026 and December 31, 2030.
- Biomarker or test result
- The disease must be Epstein-Barr virus-positive.
Main reasons for not taking part
- Past cohort: no usable survival follow-up information
- Past cohort: survival status cannot be confirmed
- New cohort: unwilling or unable to take part in the planned follow-up
- New cohort: no written informed consent or no baseline blood sample
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age 18 years or older
- Newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease meeting World Health Organization diagnostic criteria
- For the retrospective cohort: diagnosis of extranodal NK/T-cell lymphoma between January 1, 2017 and December 31, 2025 at a participating center
- For the prospective cohort: diagnosis between June 1, 2026 and December 31, 2030 of one of the following:
- Extranodal NK/T-cell lymphoma
- Aggressive NK-cell leukemia
- Systemic chronic active Epstein-Barr virus disease of T/NK-cell type; or Epstein-Barr virus-positive nodal T/NK-cell lymphoma
- Availability of essential diagnostic, staging, and treatment information
- For the prospective cohort: written informed consent and successful collection of the protocol-required baseline peripheral blood specimen
Who cannot take part
- For the retrospective cohort: no usable survival follow-up information, inability to confirm survival status, or inability to calculate the principal survival outcomes
- For the prospective cohort: unwillingness or inability to participate in protocol-defined longitudinal clinical follow-up
Where in China
- Fudan University Shanghai Cancer CenterShanghai, ChinaContact: Rong Tao, MDTaking people
About the trial
What the trial wants to find out
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases. The study consists of a retrospective clinical cohort of 500 consecutively diagnosed patients with extranodal NK/T-cell lymphoma and a prospective clinical-biological cohort of 1,000 newly diagnosed patients with extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, or Epstein-Barr virus-positive nodal T/NK-cell lymphoma.
Read full original descriptionShow less
The study will characterize clinical features, treatment pathways, response, relapse or progression patterns, and long-term survival. The prospective cohort will additionally undergo standardized collection of peripheral blood and optional tumor tissue specimens at predefined clinical time points. Clinical, molecular, viral, and immune biomarkers will be evaluated for their associations with treatment response, treatment failure, disease progression, and survival. No treatment is assigned by the study.
The 2 groups in the trial
- Retrospective NKTCL Cohort
Approximately 500 consecutive hospitalized patients with newly diagnosed extranodal NK/T-cell lymphoma diagnosed between January 1, 2017 and December 31, 2025. Clinical, treatment, response, relapse, safety, and survival information is collected from medical records and follow-up records. No biospecimen collection is mandated.
- Prospective EBV-Positive T/NK Disease Cohort
Approximately 1,000 consecutive newly diagnosed patients enrolled between June 1, 2026 and December 31, 2030. Eligible diseases include extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, and Epstein-Barr virus-positive nodal T/NK-cell lymphoma. Clinical information, longitudinal outcomes, and protocol-defined biospecimens are collected. Extranodal NK/T-cell lymphoma will represent at least 80% of this cohort.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter Ambidirectional Clinical and Biological Cohort Study of Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Diseases
- Plain-language title
- Following People With Epstein-Barr Virus-Related T/NK-Cell Lymphoma and Related DiseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 August 2026